MEDPACE HOLDINGS INC (MEDP) Stock Fundamental Analysis
USA - NASDAQ:MEDP - US58506Q1094 - Common Stock
584.57 USD
+4.04 (+0.7%)
584.57 USD
0 (0%)
Taking everything into account, MEDP scores 7 out of 10 in our fundamental rating. MEDP was compared to 58 industry peers in the Life Sciences Tools & Services industry. Both the health and profitability get an excellent rating, making MEDP a very profitable company, without any liquidiy or solvency issues. MEDP is growing strongly while it is still valued neutral. This is a good combination! This makes MEDP very considerable for growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year MEDP was profitable.
In the past year MEDP had a positive cash flow from operations.
In the past 5 years MEDP has always been profitable.
In the past 5 years MEDP always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 24.70%, MEDP belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
MEDP's Return On Equity of 147.46% is amongst the best of the industry. MEDP outperforms 100.00% of its industry peers.
MEDP has a Return On Invested Capital of 91.45%. This is amongst the best in the industry. MEDP outperforms 100.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for MEDP is significantly above the industry average of 13.49%.
The last Return On Invested Capital (91.45%) for MEDP is above the 3 year average (38.75%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.7% | ||
| ROE | 147.46% | ||
| ROIC | 91.45% |
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
1.3 Margins
With an excellent Profit Margin value of 18.36%, MEDP belongs to the best of the industry, outperforming 93.10% of the companies in the same industry.
MEDP's Profit Margin has improved in the last couple of years.
The Operating Margin of MEDP (21.50%) is better than 89.66% of its industry peers.
MEDP's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 31.11%, MEDP is doing worse than 70.69% of the companies in the same industry.
In the last couple of years the Gross Margin of MEDP has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.5% | ||
| PM (TTM) | 18.36% | ||
| GM | 31.11% |
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MEDP is creating value.
Compared to 1 year ago, MEDP has less shares outstanding
The number of shares outstanding for MEDP has been reduced compared to 5 years ago.
There is no outstanding debt for MEDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
MEDP has an Altman-Z score of 8.20. This indicates that MEDP is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 8.20, MEDP belongs to the top of the industry, outperforming 89.66% of the companies in the same industry.
There is no outstanding debt for MEDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 8.2 |
ROIC/WACC8.74
WACC10.46%
2.3 Liquidity
MEDP has a Current Ratio of 0.57. This is a bad value and indicates that MEDP is not financially healthy enough and could expect problems in meeting its short term obligations.
MEDP has a Current ratio of 0.57. This is amonst the worse of the industry: MEDP underperforms 96.55% of its industry peers.
MEDP has a Quick Ratio of 0.57. This is a bad value and indicates that MEDP is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.57, MEDP is not doing good in the industry: 93.10% of the companies in the same industry are doing better.
The current and quick ratio evaluation for MEDP is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.57 | ||
| Quick Ratio | 0.57 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 25.22% over the past year.
Measured over the past years, MEDP shows a very strong growth in Earnings Per Share. The EPS has been growing by 33.22% on average per year.
MEDP shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.88%.
Measured over the past years, MEDP shows a quite strong growth in Revenue. The Revenue has been growing by 19.62% on average per year.
EPS 1Y (TTM)25.22%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%28.24%
Revenue 1Y (TTM)13.88%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%23.74%
3.2 Future
MEDP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.11% yearly.
MEDP is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.93% yearly.
EPS Next Y13.61%
EPS Next 2Y11.45%
EPS Next 3Y10.95%
EPS Next 5Y10.11%
Revenue Next Year16.94%
Revenue Next 2Y12.85%
Revenue Next 3Y11.44%
Revenue Next 5Y10.93%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 40.88 indicates a quite expensive valuation of MEDP.
60.34% of the companies in the same industry are more expensive than MEDP, based on the Price/Earnings ratio.
MEDP's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.76.
The Price/Forward Earnings ratio is 37.26, which means the current valuation is very expensive for MEDP.
MEDP's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. MEDP is cheaper than 63.79% of the companies in the same industry.
MEDP is valuated expensively when we compare the Price/Forward Earnings ratio to 22.63, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.88 | ||
| Fwd PE | 37.26 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MEDP indicates a somewhat cheap valuation: MEDP is cheaper than 60.34% of the companies listed in the same industry.
MEDP's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MEDP is cheaper than 82.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.26 | ||
| EV/EBITDA | 30.13 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates MEDP does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of MEDP may justify a higher PE ratio.
PEG (NY)3
PEG (5Y)1.23
EPS Next 2Y11.45%
EPS Next 3Y10.95%
5. Dividend
5.1 Amount
No dividends for MEDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
584.57
+4.04 (+0.7%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners94.93%
Inst Owner Change0.58%
Ins Owners0.54%
Ins Owner Change-1.31%
Market Cap16.42B
Revenue(TTM)2.36B
Net Income(TTM)433.00M
Analysts52.94
Price Target519.85 (-11.07%)
Short Float %7.53%
Short Ratio5.03
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.04%
Min EPS beat(2)2.57%
Max EPS beat(2)7.52%
EPS beat(4)4
Avg EPS beat(4)12.38%
Min EPS beat(4)2.57%
Max EPS beat(4)21.62%
EPS beat(8)8
Avg EPS beat(8)12.23%
EPS beat(12)11
Avg EPS beat(12)11.91%
EPS beat(16)15
Avg EPS beat(16)13.95%
Revenue beat(2)2
Avg Revenue beat(2)5.36%
Min Revenue beat(2)0.93%
Max Revenue beat(2)9.78%
Revenue beat(4)3
Avg Revenue beat(4)3.28%
Min Revenue beat(4)-1.63%
Max Revenue beat(4)9.78%
Revenue beat(8)3
Avg Revenue beat(8)0.43%
Revenue beat(12)7
Avg Revenue beat(12)1.26%
Revenue beat(16)9
Avg Revenue beat(16)1.1%
PT rev (1m)-0.04%
PT rev (3m)40.56%
EPS NQ rev (1m)0.27%
EPS NQ rev (3m)17.29%
EPS NY rev (1m)0.08%
EPS NY rev (3m)10.4%
Revenue NQ rev (1m)0.08%
Revenue NQ rev (3m)18%
Revenue NY rev (1m)0.08%
Revenue NY rev (3m)12.74%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.88 | ||
| Fwd PE | 37.26 | ||
| P/S | 6.96 | ||
| P/FCF | 24.26 | ||
| P/OCF | 23.09 | ||
| P/B | 55.92 | ||
| P/tB | N/A | ||
| EV/EBITDA | 30.13 |
EPS(TTM)14.3
EY2.45%
EPS(NY)15.69
Fwd EY2.68%
FCF(TTM)24.09
FCFY4.12%
OCF(TTM)25.32
OCFY4.33%
SpS83.96
BVpS10.45
TBVpS-14.33
PEG (NY)3
PEG (5Y)1.23
Graham Number58
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.7% | ||
| ROE | 147.46% | ||
| ROCE | 108.09% | ||
| ROIC | 91.45% | ||
| ROICexc | 233.48% | ||
| ROICexgc | N/A | ||
| OM | 21.5% | ||
| PM (TTM) | 18.36% | ||
| GM | 31.11% | ||
| FCFM | 28.7% |
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
ROICexc(3y)71.87%
ROICexc(5y)52.56%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)47.22%
ROCE(5y)35.45%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y64.05%
ROICexc growth 5Y48.31%
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
F-Score8
Asset Turnover1.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 120.93% | ||
| Cap/Sales | 1.46% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 132.81% | ||
| Profit Quality | 156.3% | ||
| Current Ratio | 0.57 | ||
| Quick Ratio | 0.57 | ||
| Altman-Z | 8.2 |
F-Score8
WACC10.46%
ROIC/WACC8.74
Cap/Depr(3y)142.96%
Cap/Depr(5y)144.54%
Cap/Sales(3y)2.07%
Cap/Sales(5y)2.41%
Profit Quality(3y)141.71%
Profit Quality(5y)142.32%
High Growth Momentum
Growth
EPS 1Y (TTM)25.22%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%28.24%
EPS Next Y13.61%
EPS Next 2Y11.45%
EPS Next 3Y10.95%
EPS Next 5Y10.11%
Revenue 1Y (TTM)13.88%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%23.74%
Revenue Next Year16.94%
Revenue Next 2Y12.85%
Revenue Next 3Y11.44%
Revenue Next 5Y10.93%
EBIT growth 1Y24.03%
EBIT growth 3Y31.04%
EBIT growth 5Y28.55%
EBIT Next Year22.27%
EBIT Next 3Y13.24%
EBIT Next 5Y12.21%
FCF growth 1Y79.18%
FCF growth 3Y34.54%
FCF growth 5Y25.47%
OCF growth 1Y71.92%
OCF growth 3Y32.23%
OCF growth 5Y24.7%
MEDPACE HOLDINGS INC / MEDP FAQ
What is the fundamental rating for MEDP stock?
ChartMill assigns a fundamental rating of 7 / 10 to MEDP.
What is the valuation status of MEDPACE HOLDINGS INC (MEDP) stock?
ChartMill assigns a valuation rating of 4 / 10 to MEDPACE HOLDINGS INC (MEDP). This can be considered as Fairly Valued.
How profitable is MEDPACE HOLDINGS INC (MEDP) stock?
MEDPACE HOLDINGS INC (MEDP) has a profitability rating of 9 / 10.
Can you provide the expected EPS growth for MEDP stock?
The Earnings per Share (EPS) of MEDPACE HOLDINGS INC (MEDP) is expected to grow by 13.61% in the next year.